<DOC>
	<DOCNO>NCT00364676</DOCNO>
	<brief_summary>This Phase 1 study determine safety , tolerability , pharmacokinetics vinorelbine liposome injection ( VLI ) patient advance solid tumor , non-Hodgkin 's lymphoma , Hodgkin 's disease .</brief_summary>
	<brief_title>Study Vinorelbine Liposomes Injection Advanced Solid Tumors , Non-Hodgkin 's Lymphoma Hodgkin 's Disease</brief_title>
	<detailed_description>The objective study : - To assess safety tolerability treatment VLI . - To determine maximum tolerate dose ( MTD ) VLI . - To characterize pharmacokinetic ( PK ) profile VLI . - To explore preliminary tumor response VLI .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>1 . Histologically confirm solid tumor refractory standard therapy standard therapy know exist , relapse and/or refractory nonHodgkin 's lymphoma Hodgkin 's disease 2 . Adequate hematologic , hepatic renal function define laboratory test . 3 . At least 18 year age . 4 . Have life expectancy least 12 week . 5 . Patients must give write informed consent . 6 . ECOG Zubrod performance status 0 , 1 , 2 . 1 . Primary tumor central nervous system ( CNS ) . Symptomatic brain metastasis ( unless patient stable without requirement steroid and/or antiseizure medication least 3 month ) leptomeningeal tumor involvement . 2 . Prior chemotherapy radiotherapy within 4 week prior study entry ( 6 week nitrosoureas mitomycin C ) . 3 . Planned concurrent systemic therapy and/or radiotherapy drug study treatment . 4 . Use investigational drug , biologics device within 28 day prior study treatment plan use course study . 5 . Active infection serious underlie medical condition , would impair ability patient receive protocol treatment . 6 . Prophylactic hematologic growth factor administer less equal 2 week prior start therapy VLI ( exclude darbepoetin alfa , epoetin alfa ) . 7 . Female patient pregnant lactate . 8 . Dementia significantly alter mental status would prohibit understanding give informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Vinorelbine</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Hodgkins</keyword>
	<keyword>Non hodgkin</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>